Latest Coagulation Stories
Timeline for Hemophilia B IND Application Filing Targeting Second Quarter 2015 RICHMOND, Calif., Sept. 10, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
Kristine Kraft, partner at Schlichter, Bogard & Denton, LLP, reports on the findings of a new study published in the Journal of Neurosurgery regarding the increased difficulties of stopping
- Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Regimens of Either Every Three to Five Days or Once-Weekly Infusions - MISSISSAUGA, ON, Aug.
Zoll, Kranz & Borgess, LLC, (ZKB), an experienced pharmaceutical and medical device litigation firm, is currently investigating claims of individuals who developed bleeding, clotting or other
SOUTH SAN FRANCISCO, Calif., July 16, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.
First Recombinant Treatment Approved in US for Patients With GT With Refractoriness to Platelet Transfusions, With or Without Antibodies to Platelets PLAINSBORO, N.J., July 7, 2014 /PRNewswire/
LONDON, June 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Transparency Market Research added a new report "Hemophilia Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store.
Seven-fold lower incidence of VTEs in patients treated with ISIS-FXIRx compared to enoxaparin CARLSBAD, Calif., May 22, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
- Kogenate® FS antihemophilic factor (recombinant) approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A WHIPPANY,
- An armed gangster.